Carine J.M. Doggen

Showing 1-8 of 8 articles

Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial

Kok M, Zocca P, Buiten R, Danse PW, Schotborgh C, Scholte M, Hartmann M, Stoel M, van Houwelingen K, Linssen GCM, Doggen CJM, von Birgelen C

October 19, 2018 | 10.4244/EIJ-D-18-00336

Stents and scaffolds

Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population

Kok M, von Birgelen C, Sattar N, Zocca P, Löwik M, Danse PW, Schotborgh C, Scholte M, Hartmann M, Kant GD, Doelman CJA, Gin M, Stoel M, van Houwelingen K, Linssen GCM, IJzerman M, Doggen CJM, van der Heijden LC

October 12, 2018 | 10.4244/EIJ-D-17-01067

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT

Zocca P, van der Heijden LC, Kok M, Löwik M, Hartmann M, Stoel M, Louwerenburg H, de Man F, Linssen GCM, Knottnerus I, Doggen CJM, van Houwelingen K, von Birgelen C

November 20, 2017 | 10.4244/EIJ-D-17-00634

Coronary interventions

Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial

van der Heijden LC, Kok M, Löwik M, Danse PW, Jessurun G, Hautvast R, van Houwelingen K, Stoel M, Hartmann M, Linssen GCM, Doggen CJM, von Birgelen C

April 20, 2017 | 10.4244/EIJ-D-16-00571

Coronary interventions

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial

Tandjung K, Lam MK, Sen H, de Man F, Louwerenburg H, Stoel M, van Houwelingen K, Linssen GCM, van der Palen J, Doggen CJM, von Birgelen C

July 20, 2016 | 10.4244/EIJY15M08_01

Coronary interventions

Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study

Kok M, von Birgelen C, Lam MK, Löwik M, van Houwelingen K, Stoel M, Louwerenburg H, de Man F, Hartmann M, Doggen CJM, van Til J, IJzerman M

April 20, 2016 | 10.4244/EIJY15M10_06

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

Löwik M, Lam MK, Sen H, Tandjung K, van Houwelingen K, de Man F, Stoel M, Louwerenburg H, Linssen GCM, Doggen CJM, von Birgelen C

March 20, 2015 | 10.4244/EIJY14M08_11

Assessment of the relation between initial culprit vessel patency in acute ST-elevation myocardial infarction and endothelial function

Kandhai-Ragunath J, Jorstad H, de Wagenaar B, de Man F, Stoel M, van Es J, Doelman CJA, Doggen CJM, Peters R, von Birgelen C

November 20, 2014 | 10.4244/EIJV10I7A137

1

Latest news

The ISCHEMIA trial in real-world practice, a new “uncaging” coronary stent, PCI of the LM trifurcation in the EXCEL trial and more...

December 18, 2020

Elective Cardiac Invasive Procedures during the COVID-19 Outbreak

A. Chieffo et al.

January 8, 2021

Addressing interventional periprocedural anxiety with virtual reality

January 13, 2021

SCOPE 2, BASKET-SMALL 2 3 years, ALPHEUS, COMPARE-ABSORB, DUBIUS

(Thanks to the support of Biotronik)

January 13, 2021

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

Translating ISCHEMIA into practice

William E. Boden

January 13, 2021

This Week's JAA's: BIOFREEDOM-QCA trial, TTVr with the TriClip/MitraClip G4 System, Numerical prediction of coronary artery compression in TPVI...

January 12, 2021

Valvular disease